SODIUM BICARBONATE INFUSION: TO PREVENT CARDIAC SURGERY-ASSOCIATED ACUTE KIDNEY INJURY

Ramesh Patel¹, Ritesh Shah², Jignesh Kothari³, Harshil Joshi⁴, Rajesh Thosani⁵, Himani Pandya⁶, Atul Solanki⁷

HOW TO CITE THIS ARTICLE:
Ramesh Patel, Ritesh Shah, Jignesh Kothari, Harshil Joshi, Rajesh Thosani, Himani Pandya, Atul Solanki. “Sodium Bicarbonate Infusion: To Prevent Cardiac Surgery-Associated Acute Kidney Injury”. Journal of Evolution of Medical and Dental Sciences 2015; Vol. 4, Issue 17, February 26; Page: 2912-2921, DOI: 10.14260/jemds/2015/421

ABSTRACT: OBJECTIVES: The incidence of cardiac surgery–associated acute kidney injury is 50% of patients and is associated with increased mortality and morbidity. This study aimed to determine if perioperative urinary and plasma alkalization with sodium bicarbonate infusion reduces the incidence of cardiac surgery–associated acute kidney injury. SETTING AND DESIGN: This study is double blind randomized control trial conducted at U N Mehta Institute of Cardiology and Research Center, India. METHODS AND RESULT: A total of 140 patients scheduled to undergo elective cardiac surgery, who were at increased risk of development of cardiac surgery–associated acute kidney injury using recognized risk factors. Patients were randomly allocated to receive either sodium bicarbonate (n = 70) or sodium chloride (n = 70) infusion, commencing at the start of anesthesia, in a dose of 4 mmol/kg over 24 hour. The primary outcome measure was the number of patients with development of CSA-AKI, defined as an increase in creatinine greater than 25% from baseline to peak value within the first three postoperative days. Significant differences among the groups in both plasma and urinary pH were achieved 6 hours after commencement of the infusion, and these changes persisted for more than 24 hours. A total of 7 out of 70(10%) patients in the sodium bicarbonate group and 16 out of 70(22.85%) patients in the sodium chloride group developed acute kidney injury within the first three postoperative days with p value of 0.06 which is statistically not significant. There were also no significant differences in ventilation hours, ICU or hospital length of stay, or mortality. CONCLUSIONS: Perioperative alkalization of blood and urine using an infusion of sodium bicarbonate did not result in a decrease in the incidence of acute kidney injury in patients undergoing cardiac surgery. KEYWORDS: Acute kidney injury; Cardiac surgery; Cardiopulmonary bypass; Creatinine; outcome; Urinary output.

INTRODUCTION: Cardiac surgery using cardio-pulmonary bypass is one of the most common and major surgical procedures worldwide. The likelihood of cardiac surgery associated with acute kidney injury (CSA-AKI) requiring dialysis following cardiac surgery varies greatly. Acute kidney injury is a global health problem with more than 10 million people affected annually and estimated 4 million people die of acute kidney injury each year. Acute renal dysfunction is a common and serious postoperative complication of cardiopulmonary bypass and may affect 25-40% of patients.(1,2,3) Evidence suggests that even minimal increase in serum creatinine is associated with poorer outcomes.(4,5) AKI induces injury to distant organs such as lungs, heart and brain. Many causes of cardio pulmonary bypass associated acute renal dysfunction have been proposed such as ischemia-reperfusion, generation of reactive oxygen species, hemolysis and activation of inflammatory pathways.(6,7,8,9) Till date no safe, simple and effective intervention for prevention of cardiopulmonary bypass- associated acute renal dysfunction has been found.(10,11,12,13)
Urinary acidity may enhance the generation and toxicity of reactive oxygen species induced by cardio pulmonary bypass and may also participated in renal injury. Urinary alkalization by using sodium bicarbonate may protect from renal injury induced by oxidant substances, iron mediated free radical pathways, and compliment activation and tubular hemoglobin cast formation.(8,9)

The mechanism behind these observed protective effects is thought to relate to the ability of bicarbonate to alkalinize the urine and to slow the Haber-weiss reaction that generate reactive oxygen species via iron-dependent pathways.(14,15) Mechanism of action for sodium bicarbonate are supported by the findings from a large meta-analysis in contrast nephropathy (Another form of acute kidney injury), demonstrating a positive outcome.(16)

Accordingly we hypothesized that urinary alkalization might protect kidney function in patients at increased risk of acute renal dysfunction undergoing cardiopulmonary bypass and conducted a randomized controlled trial with perioperative sodium bicarbonate infusion.

MATERIAL METHODS: Study was approved by our institutional ethics committee and informed and written consent was obtained from all the patients. Study was done in the period of August 2013 to November 2014 at U.N. Mehta institute of cardiology and research center, Ahmedabad. This study was a double-blind, randomized controlled trial designed to assess if the administration of sodium bicarbonate as a continuous infusion commenced prior to cardiopulmonary bypass would result in less postoperative acute renal dysfunction in patients undergoing cardiac surgery. This prospective study enrolled 140 consecutive patients who underwent on pump cardiac surgery. A Microsoft Excel–based (Microsoft Corp., Redmond, WA) random-number generator was used to create the randomization list.

Allocation concealment to patients, anesthesiologists, cardiac surgeons, intensive care specialists, bedside nurses, and investigators was ensured. Treatment allocation was only revealed after the study had been completed, the database locked, and statistical analysis completed. Research Randomizer online random number generator was used to create the randomization. All the patients were randomly divided in to two group. One was study group in all the patients were given NaHCO3 and another group is control group in all the patients were given NaCl. NaHCO3 group of Patients received a dose of 4 mmol/kg body weight over 24 hour. And NaCl group of patients received same amount of NaCl.

| Inclusion criteria               | Exclusion criteria:                                                                 |
|---------------------------------|------------------------------------------------------------------------------------|
| Age >40 year                    | End-stage renal disease (plasma creatinine concentration > 3.4 mg/dL)               |
| New York Heart Association class III/IV or impaired left ventricular function (left ventricular ejection fraction < 40%) | Emergency cardiac surgery                                                        |
| Valvular surgery or concomitant valvular and coronary artery bypass graft surgery | Known blood-borne infectious disease                                                |
| Redo cardiac surgery            | Planned off-pump cardiac surgery                                                   |
| Insulin-dependent diabetes mellitus | Chronic inflammatory disease on immunosuppression                                  |
|                                 | Age < 18 year                                                                       |

Inclusion and exclusion criteria shown in this table
Despite of this addition of the infusion of the study drug, there were no change to normal clinical practice i.e. anesthesia technique, including pre-operative and post-operative medication given by the attending anesthetist. Surgical approach and cardiopulmonary bypass was conducted on bases of standard technique of our institute. And post-operative care like hemodynamic monitoring, analgesic medication, and fluid all were carried out by intensivist and nursing staff as per institute protocol.

Data Collection: The primary outcome measure was the number of patients who had postoperative AKI development. This was defined as an increase in plasma creatinine concentration greater than 25% from baseline to peak value at any time within the first 3 days after cardiopulmonary bypass.

Data collected included age (Days), weight (kilograms), sex, height, preoperative creatinine postoperative creatinine on day 1 day 2 and day 3 and its creatinine clearance. As well as mean arterial pressure, pH, urea and bicarbonate. CPB time, cross clamp time, mechanical ventilation time (hours), intensive care unit (ICU) stay (hours), and hospital stay also collected. Postoperative morbidity and mortality data were also collected.

The occurrence of specific adverse events including the prevalence of hypernatremia ([Na+] >150 mmol/L), hypokalemia ([K+] < 3.5 mmol/L), alkalemia (pH > 7.50), postoperative atrial fibrillation, and other postoperative arrhythmias (supraventricular arrhythmias, ventricular tachycardia and ventricular fibrillation) during the first 3 postoperative days were recorded.

STATISTICS: The statistical analysis was performed using SPSS v20.0. The values were expressed as Mean±sd. To compare the data between two groups one sample t test were used. Independent-sample t test were used to compare the categorical variables. ‘p’ <0.05 was considered statistically significant.

RESULT: The patients were distributed into two groups on the basis of either they received sodium bicarbonate or sodium chloride.

No statistical difference between the groups was detected in terms of age (41.84 ± 13.762 vs 46.77 ± 13.249) days, P=0.331; age range, 16 year -80 years), weight (49.17 ± 10.413vs 56.17 ± 17.666 kg, P =0.183, and duration of CPB (93.2857 ± 33.79913 vs 105.8429 ± 41.68955 minutes, P=0.270) and in cross clamp time (67.1143 ± 27.20110 vs 75.9143 ± 37.93539 minutes, P=0.079) which is shown in Table.1, 3.

Significant differences in urinary pH and plasma pH from baseline to 48 hours were found between the two groups. Sodium bicarbonate infusion induced urinary alkalization 6 and 24 hours after commencement of study drug infusion which is shown in Figure (1, 2). And 3 patients from each group needed renal replacement therapy but they died during hospital stay due to multi organ dysfunction.

There was a no significant differences found in preoperative and postoperative metabolic profile such as, serum creatinine and creatinine clearance, urea, mean arterial pressure (Table.2, 3).

A total of 7 out of 70(10%) patients in the sodium bicarbonate group and 16 out of 70(22.85%) patients in the sodium chloride group developed acute kidney injury within the first three postoperative days with p value of 0.06 which is statistically not significant. Overall, 16.42 % of patients had an increase of creatinine greater than 0.5 mg/dl. Urine output was comparable for the two groups.
There was no significance difference found in mechanical ventilator stay \((8.47 \pm 5.296 \text{ vs } 8.14 \pm 5.787 \text{ hours}, \text{P}=0.317)\), duration of ICU stay \((3.67 \pm 1.271 \text{ vs } 3.83 \pm 2.085 \text{ days}, \text{P}=0.341)\) and in duration of hospital stay \((19.71 \pm 7.410 \text{ vs } 18.47 \pm 5.115 \text{ days}, \text{P}=0.124)\). (Table.3). We did not find any adverse events or safety concerns during this study.

DISCUSSION: AKI is not only a frequent complication in cardiac surgical patients\(^{(17)}\) but has also been associated with morbidity and mortality independently.\(^{(18,19)}\) Unfortunately, there is not much progress within the last years in the development of strategies to reduce the incidence and improve the prognosis of this complication. Recently, Haase and coworkers have elegantly delineated a pathophysiological line of evidence that the severity of the renal insult induced by on-pump cardiac surgery may, at least in part, be related to the degree of hemoglobinuria: the histological features of CSA-AKI resemble the pigment nephropathy typically observed during rhabdomyolysis.\(^{(20)}\) Since alkalization of the urine is among the best treatment option available to treat rhabdomyolysis\(^{(21)}\) they used this concept successfully as a strategy for the prevention of CSA-AKI in a small pilot trial.\(^{(22)}\)

And the fact that urine alkalization for the treatment of rhabdomyolysis has a longstanding tradition in clinical medicine.\(^{(21)}\) As per their promising findings and the relatively high incidence of CSA-AKI at our institution with the lack of other available measures for preventing renal dysfunction during cardiac surgery,\(^{(23)}\) we chose to implement this concept into our clinical study. It is of note that an interdisciplinary working group on this topic also gave a positive recommendation to use hydration and bicarbonate to reduce the nephrotoxic effects of myoglobinuria.\(^{(24)}\)

We conducted a double-blind, randomized controlled trial to investigate whether perioperative sodium bicarbonate infusion to achieve urinary alkalization could attenuate the creatinine rise associated with cardiopulmonary bypass in cardiac surgical patients. In this randomized controlled trial, we found that the infusion of sodium bicarbonate commencing before cardiopulmonary bypass and continuing postoperatively for a total of 24 hours achieved serum and urinary alkalization but did not reduce kidney damage, defined as a rise in serum creatinine during the first three postoperative days.

Previous single-center double-blind controlled study demonstrated that sodium bicarbonate administration may reduce CSA-AKI, however this was not confirmed in our study. It is interesting to note that the use of sodium bicarbonate to prevent CIN has shown positive results in several small single-centre studies, but these also have not been replicated consistently in larger studies.

We did not used any scoring systems to define AKI but we used the same risk factors that were used in other studies.\(^{(25)}\) The administration of sodium bicarbonate by continuous infusion did produce alkalization of both blood and urine. This was clinically relevant and statistically significant at all-time points beyond baseline. The degree of these physiological effects was similar to that observed in the other study. In our study, patients with increased risk of CSA-AKI development was identified, a biochemical effect consistent with the proposed mechanism of action was produced, and excellent separation between the two groups for the biochemical endpoints was maintained.

A similar pattern of risk factors for postoperative acute kidney dysfunction as described in the largest randomized controlled trial in the prevention of this postoperative complication was found.\(^{(11)}\) This observation confirms that the selected patient population was at increased risk of acute kidney dysfunction.
This study demonstrates that there is no reduction of CSA-AKI in patients who are administered sodium bicarbonate despite achieving adequate plasma and urinary alkalization. Therefore, we cannot recommend the routine prophylactic use of this therapy in patients undergoing cardiac surgery.

CONCLUSION: In patients at high risk of CSA-AKI, bicarbonate infusion alkalinized both blood and urine but did not result in a decrease in the prevalence of CSA-AKI. On this basis of these results, we have concluded that, the use of perioperative infusions of sodium bicarbonate may not reduce the CSA-AKI in this patient group.

REFERENCES:

1. Chertow GM, Levy EM, Hammermeister KE, Grover F, Daley J. Independent association between acute renal failure and mortality following cardiac surgery. Am J Med. 1998; 104:343–348.
2. Stafford-Smith M, Podgoreanu M, Swaminathan M, Phillips-Bute B, Mathew JP, Hauser EH, et al; Perioperative Genetics and Safety Outcomes Study (PEGASUS) Investigative Team: Association of genetic polymorphisms with risk of renal injury after coronary bypass graft surgery. Am J Kidney Dis. 2005; 45:519–530.
3. Ghotkar SV, Grayson AD, Fabri BM, Dihmis WC, Pullan DM: Preoperative calculation of risk for prolonged intensive care unit stay following coronary artery bypass grafting. J Cardiothorac Surg. 2006; 1:14.
4. Lassnigg A, Schmidlin D, Mouhieddine M, Bachmann LM, Druml W, Bauer P, et al: Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: A prospective cohort study. J Am Soc Nephrol. 2004; 15:1597–1605.
5. Zanardo G, Michielon P, Paccagnella A, Rosi P, Caló M, Salandin V, et al. Acute renal failure in the patient undergoing cardiac operation. Prevalence, mortality rate, and main risk factors. J Thorac Cardiovasc Surg. 1994; 107:1489–1495.
6. Doi K, Suzuki Y, Nakao A, Fujita T, Noiri E. Radical scavenger edaravone developed for clinical use ameliorates ischemia/reperfusion injury in rat kidney. Kidney Int. 2004; 65:1714–1723.
7. McCord JM: Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med. 1985; 312:159–163.
8. Zager RA, Gamelin LM: Pathogenetic mechanisms in experimental hemoglobinuric acute renal failure. Am J Physiol. 1989; 256(3 Pt 2):F446–F455.
9. Paller MS: Hemoglobin- and myoglobin-induced acute renal failure in rats: Role of iron in nephrotoxicity. Am J Physiol. 1988; 255(3 Pt 2):F539–F544.
10. Bove T, Landoni G, Calabrò MG, Aletti G, Marino G, Cerchierini E, et al: Renoprotective action of fenoldopam in high-risk patients undergoing cardiac surgery: A prospective, double-blind, randomized clinical trial. Circulation. 2005; 111:3230–3235.
11. Burns KE, Chu MW, Novick RJ, Fox SA, Gallo K, Martin CM, et al: Perioperative N-acetylcysteine to prevent renal dysfunction in high-risk patients undergoing CABG surgery: a randomized controlled trial. JAMA. 2005; 294: 342–350.
12. Haase M, Haase-Fielitz A, Bagshaw SM, Reade MC, Morgera S, Seevenayagam S, et al: Phase II, randomized, controlled trial of high-dose N-acetylcysteine in high-risk cardiac surgery patients. Crit Care Med. 2007; 35:1324–1331.

13. Mentzer RM, Oz MC, Sladen RN, Graeve AH, Hebeler RF, Lubener JM, et al; NAPA Investigators: Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: The NAPA Trial. J Am Coll Cardiol. 2007; 49:716–726.

14. Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, et al: Prevention of contrast induced nephropathy with sodium bicarbonate: A randomized controlled trial. JAMA. 2004; 291:2328–2334.

15. Brar SS, Shen AY, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N, et al: Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: A randomized trial. JAMA. 2008; 300:1038–1046.

16. Pascal Meier, Dennis T Ko, Akira Tamura, Umesh Tamhane, Hitinder S Gur. Sodium bicarbonate-based hydration prevents contrast-induced nephropathy: A meta-analysis. BMC Med. 2009; 7:23.

17. Heringlake M, Knappe M, Vargas Hein O, Lufth H, Kindgen-Milles D, Böttiger BW, et al. Renal dysfunction according to the ADQI-RIFLE system and clinical practice patterns after cardiac surgery in Germany. Minerva Anestesiol. 2006, 72:645-654.

18. Chertow GM, Levy EM, Hammermeister KE, Grover F, Daley J: Independent association between acute renal failure and mortality following cardiac surgery. Am J Med. 1998, 104:343-348.

19. Lassnigg A, Schmidlin D, Mouhieddine M, Bachmann LM, Druml W, Bauer P, et al. Impact of minimal increases in serum creatinine on outcome in patients after cardiothoracic surgery: Do we have to revise current definitions of acute renal failure? Crit Care Med. 2008, 36:1129-1137.

20. Haase M, Haase-Fielitz A, Bagshaw SM, Ronco C, Bellomo R: Cardiopulmonary bypass-associated acute kidney injury: a pigment nephropathy? Contrib Nephrol. 2007, 156:340-353.

21. Vanholder R, Sever M, Erek E: Rhabdomyolysis. J Am Soc Nephrol 2000, 11:1553-1561.

22. Haase M, Haase-Fielitz A, Bellomo R, Devarajan P, Story D, Matalanis G, et al. Sodium bicarbonate to prevent increases in serum creatinine after cardiac surgery: a pilot double-blind, randomized controlled trial. Crit Care Med. 2009; 37:39-47.

23. Schetz M, Bove T, Morelli A, Mankad S, Ronco C, Kellum JA: Prevention of cardiac surgery associated acute kidney injury. Int J Artif Organs. 2008, 31:179-189.

24. Heringlake M, Kindgen-Milles D, Hackmann F, Haake N, Kielstein J, Lance M, et al. Pathophysiology, prophylaxis, and treatment of cardiac surgery-associated kidney injury. Position of the working group renal failure of the collaborative group Cardiothoracic Intensive Care of the DGAI and DGGTHG on the consensus statement of the Acute Dialysis Quality Initiative. Z Herz-Thorax-Gefäßchir. 2009, 23:349-373.

25. Haase M, Haase-Fielitz A, Bellomo R, Devarajan P, Story D, Matalanis G, et al: Sodium bicarbonate to prevent increases in serum creatinine after cardiac surgery: A pilot double blind, randomized controlled trial. Crit Care Med. 2009; 37:39-47.
### Table 1: Demographic data

|                      | With NaHCO3 | Without NaHCO3 | p value |
|----------------------|-------------|----------------|---------|
| Age (year)           | 41.84 ± 13.762 | 46.77 ± 13.249 | 0.331   |
| sex                  | M=34, F=36   | M=39, F=31     |         |
| Height (cm)          | 161.09 ± 8.686 | 160.00 ± 14.022 | 0.428   |
| Weight (kg)          | 49.17 ± 10.413 | 56.17 ± 17.666 | 0.183   |

### Table 2: Primary variables

|                      | With NaHCO3 | Without NaHCO3 | P VALUE |
|----------------------|-------------|----------------|---------|
| Creatinine baseline (mg/dl) | 0.9099 ± 0.34010 | 0.9001 ± 0.25229 | P=0.24  |
| Creatinine day1(mg/dl) | 0.9671 ± 0.34453 | 1.0470 ± 0.42861 | P=0.101 |
| Creatinine day 2 (mg/dl) | 0.8683 ± 0.34365 | 0.9474 ± 0.38440 | P=0.159 |
| Creatinine day 3 (mg/dl) | 0.8304 ± 0.35251 | 0.8746 ± 0.43745 | P=0.735 |
| Creatinine clear baseline (ml/min) | 76.2126 ± 33.70187 | 77.3189 ± 22.47714 | P=0.076 |
| Creatinine clear day1 (ml/min) | 70.7376 ± 28.48894 | 71.4380 ± 26.64827 | P=0.773 |
| Creatinine clear day 2 (ml/min) | 79.6992 ± 31.35400 | 78.5197 ± 30.29545 | P=0.327 |
| Creatinine clear day 3 (ml/min) | 83.7348 ± 34.87537 | 83.5094 ± 26.86457 | P=0.299 |
| Urea baseline (mg/dl) | 31.7303 ± 16.35761 | 29.5560 ± 13.34579 | P=0.209 |
| Urea day1 (mg/dl) | 37.0034 ± 16.92377 | 38.8937 ± 18.63299 | P=0.741 |
| Urea day 2 (mg/dl) | 35.7780 ± 19.32018 | 41.6833 ± 21.28555 | P=0.158 |
| Urea day 3 (mg/dl) | 35.8784 ± 23.88313 | 38.0890 ± 23.18158 | P=0.786 |
| Urine output day1 (mg/dl) | 1.7132 ± .74410 | 1.6648 ± .71119 | P=0.789 |
| Urine output day2 (mg/dl) | 1.9475 ± .60983 | 1.7550 ± .62096 | P=0.460 |
| Urine output day 3 (mg/dl) | 1.7618 ± .61321 | 1.7153 ± .57512 | P=0.279 |
### Table 3: Secondary variables

| Variable                        | With NaHCO3 Mean ± SD | Without NaHCO3 Mean ± SD | P VALUE |
|---------------------------------|-----------------------|--------------------------|---------|
| MAP preop (mmHg)                | 81.4000 ± 11.16724    | 80.5429 ± 15.94982       | P=0.158 |
| MAP at ICU admission (mmHg)     | 80.7429 ± 13.28035    | 82.1286 ± 14.72641       | P=0.590 |
| MAP 12 hr ICU admission (mmHg)  | 78.9429 ± 10.11798    | 78.7571 ± 13.17159       | P=0.054 |
| MAP 24 hr ICU admission (mmHg)  | 75.4571 ± 13.18397    | 78.9857 ± 10.22003       | P=0.998 |
| CPB duration (min)              | 93.2857 ± 33.79913    | 105.8429 ± 41.68955      | P=0.270 |
| X clamp duration (min)          | 67.1143 ± 27.20110    | 75.9143 ± 37.93539       | P=0.079 |
| Duration of mechanical ventilation (hr) | 8.47 ± 5.296   | 8.14 ± 5.787           | P=0.317 |
| Duration of ICU stay (days)     | 3.67 ± 1.271          | 3.83 ± 2.085            | P=0.341 |
| Duration of hospital stay (days)| 19.71 ± 7.410         | 18.47 ± 5.115           | P=0.124 |

**Figure 1:** Biochemical outcome of patients receiving sodium bicarbonate compared with sodium chloride.
**Figure 2:** Biochemical outcome of patients receiving sodium bicarbonate compared with sodium chloride.
AUTHORS:
1. Ramesh Patel
2. Ritesh Shah
3. Jignesh Kothari
4. Harshil Joshi
5. Rajesh Thosani
6. Himani Pandya
7. Atul Solanki

PARTICULARS OF CONTRIBUTORS:
1. Associate Professor, Department of Cardiac Anaesthesia. U. N. Mehta Institute of Cardiology and Research Center, Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat, India.
2. Associate Professor, Department of Cardiac Anaesthesia. U. N. Mehta Institute of Cardiology and Research Center, Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat, India.
3. Associate Professor, Department of Cardio Vascular & Thoracic Surgery, U. N. Mehta Institute of Cardiology and Research Center, Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat, India.
4. DM Resident, Department of Cardiac Anaesthesia, U. N. Mehta Institute of Cardiology and Research Center, Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat, India.
5. Associate Professor, Department of Cardiac Anaesthesia, U. N. Mehta Institute of Cardiology and Research Center, Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat, India.
6. Research Assistant, Department of Research, U. N. Mehta Institute of Cardiology and Research Center, Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat, India.
7. Chief Perfusionist, Department of Perfusion, U. N. Mehta Institute of Cardiology and Research Center, Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat, India.

FINANCIAL OR OTHER COMPETING INTERESTS: None

NAME ADDRESS EMAIL ID OF THE CORRESPONDING AUTHOR:
Dr. Ramesh Patel,
U. N. Mehta Institute of Cardiology and Research Center,
Civil Hospital Campus, Asarwa,
Ahmedabad-380016, Gujarat, India.
E-mail: mitalritu15@gmail.com

Date of Submission: 24/01/2015.
Date of Peer Review: 27/01/2015.
Date of Acceptance: 17/02/2015.
Date of Publishing: 24/02/2015.